DOJ Declines Intervention in Qui Tam Lawsuit Against Corcept Therapeutics
CORT has more than doubled off its 52-week low of $28.66.
Summary
The Department of Justice has decided not to intervene in a civil qui tam action against Corcept Therapeutics, significantly reducing the potential legal and financial risk associated with the long-running lawsuit.
Key Events · Legal and Risk Events · CORT
-
DOJ Declines Intervention
The U.S. Department of Justice, along with the California Department of Insurance and other plaintiff states, filed a Notice of Election to Decline Intervention in a civil qui tam action against Corcept Therapeutics.
-
Reduced Legal Risk
This decision significantly de-escalates the legal threat from the lawsuit, which was initiated by a former employee in 2017 and involved a DOJ subpoena in 2021.
-
Lawsuit Continues
Despite the DOJ's non-intervention, the former employee (Relator) has served an amended complaint, and Corcept Therapeutics intends to vigorously defend against the claims.
Analysis · CORT · Life Sciences
The Department of Justice's decision to decline intervention in the qui tam lawsuit, which has been ongoing since 2017 and involved a subpoena in 2021, removes a major legal overhang for Corcept Therapeutics. While the former employee's lawsuit will continue, the absence of government involvement substantially reduces the potential financial penalties and reputational damage, providing a positive signal amidst recent mixed news for the company.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.7% of the 1739 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CORT was trading at $70.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $28.66 to $91.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.